Therapeutic induced neuroendocrine differentiation of prostate cancer.

Introduction. The use of selective highly effective antiandrogen drugs in castration-resistant prostate cancer (CRPC) gradually leads to cellular transformation. Objective. To study current concepts of the prevalence of neuroendocrine differentiation (NED) in patients with CRPC, as well as the treatment of this aggressive variant of PCa. Materials and methods. The results of a search in the scientific databases PubMed, in the scientific electronic library eLibrary.ru were analyzed for the following queries - keywords: treatment-induced neuroendocrine prostate cancer, treatment-emergent neuroendocrine prostate cancer, androgen receptor resistance PCa therapy, neuroendocrine prostate cancer treatment. More than 100 scientific papers published in the last 10 years were found, of which 38 were selected for this review based on the objective of the review. Results. In a number of publications, the linear plasticity of prostate adenocarcinoma (PG) in NE tumor was designated as therapy-induced prostate carcinoma (t-NEPCs). The number of observations of NED PCa is growing, including due to the widespread use of powerful aromatase inhibitors. According to a number of studies, NED PCa is